Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.44 |
| ▸ | F11 | P03951 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23242460 | 0.93 | LIPG (0.43) | LPLLIPGF11ESR2CA1 | |
| SCHEMBL23242449 | 0.89 | LPL (0.43) | LPLLIPGF11ESR2CA1 | |
| SCHEMBL17686115 | 0.82 | CYP11B2 (0.46) | LPLLIPGJAK2GRM2 | |
| SCHEMBL14659551 | 0.82 | L3MBTL1 (0.55) | LPLLIPGF11ESR2CA1 | |
| SCHEMBL18954100 | 0.82 | L3MBTL1 (0.51) | LPLLIPGF11ESR2CA1 | |
| SCHEMBL146568 | 0.78 | HRH3 (0.56) | LPLLIPGF11ESR2 | |
| SCHEMBL4900309 | 0.77 | F10 (0.45) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16880416 | 0.77 | POLB (0.54) | LPLLIPGF11ESR2CA1 | |
| SCHEMBL20745737 | 0.77 | HRH3 (0.54) | LPLLIPGF11ESR2 | |
| Hydrochloric Acid SCHEMBL5334250 | 0.77 | HRH3 (0.54) | LPLLIPGF11ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375432-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2025-12-11 | — | — | US | disclosed |
| US-12383540-B2 | Compounds that modulates AMPA receptor function | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2025-08-12 | — | — | US | disclosed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| EP-3759092-B1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2023-12-20 | — | — | EP | disclosed |
| CN-112004811-B | Compounds that modulate AMPA receptor function | 加的夫大学学院咨询有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| US-20230000847-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | DRAIG THERAPEUTICS LTD (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230000847-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | DRAIG THERAPEUTICS LTD (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2015-06-04 | — | — | US | disclosed |
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2015-06-04 | — | — | US | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-2361251-B1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TLR6, TRAF6, BMP6 | LPL 2647/4885LIPG 1481/4885F11 1650/4885 |
| US-20230000847-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | GRIN1, GRM1, GRIN2A | LPL 4362/4885LIPG 4277/4885F11 432/4885 |
| US-20250375432-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | GRIN1, GRM1, GRIN2A | LPL 4266/4885LIPG 4265/4885F11 522/4885 |
| US-12383540-B2 | Compounds that modulates AMPA receptor function | GRIN1, GRM1, GRIN2A | LPL 4362/4885LIPG 4277/4885F11 432/4885 |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | CRBN, IKZF1, IKZF3 | LPL 4398/4885LIPG 4550/4885F11 3471/4885 |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TRAF6, IL6, TLR6 | LPL 2814/4885LIPG 1673/4885F11 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.